Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$16.73 -4.9%	$19.22	$10.21 ▼ $25.67	$3.99B	0.43	3.66 million shs	3.84 million shs
ANIP ANI Pharmaceuticals	$66.30 -2.6%	$62.88	$52.50 ▼ $77.00	$1.44B	0.57	320,722 shs	326,192 shs
ANVS Annovis Bio	$2.66 -5.4%	$2.47	$1.11 ▼ $11.69	$51.64M	1.57	383,694 shs	475,137 shs
AXSM Axsome Therapeutics	$111.70 -0.5%	$106.55	$72.21 ▼ $139.13	$5.50B	0.46	666,635 shs	453,651 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	0.00%	-9.62%	-7.72%	-21.49%	+25.88%
ANIP ANI Pharmaceuticals	0.00%	+2.06%	+2.54%	-4.20%	+5.27%
ANVS Annovis Bio	0.00%	-2.28%	-1.19%	+114.35%	-78.67%
AXSM Axsome Therapeutics	0.00%	+2.50%	+8.56%	+6.93%	+33.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	3.855 of 5 stars	3.7	1.0	0.0	2.8	2.5	3.1
ANIP ANI Pharmaceuticals	3.9589 of 5 stars	2.5	1.0	3.3	3.8	3.3	1.3
ANVS Annovis Bio	1.6005 of 5 stars	3.5	1.0	0.0	0.6	1.7	0.6
AXSM Axsome Therapeutics	4.7126 of 5 stars	4.5	1.0	4.5	2.5	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	65.37% Upside
ANIP ANI Pharmaceuticals	3.00	Buy	$78.88	18.97% Upside
ANVS Annovis Bio	3.00	Buy	$18.00	577.20% Upside
AXSM Axsome Therapeutics	3.06	Buy	$172.33	54.28% Upside

Current Analyst Ratings Breakdown

Latest ANIP, ADMA, ANVS, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	ANIP ANI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$84.00
7/3/2025	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$190.00
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/10/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00
6/9/2025	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $12.00
6/9/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$153.00 ➝ $150.00
6/3/2025	AXSM Axsome Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$185.00
5/22/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00 ➝ $180.00
5/15/2025	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $17.00
5/14/2025	AXSM Axsome Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	ANIP ANI Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$86.00 ➝ $86.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	9.37	$0.54 per share	30.91	$1.48 per share	11.30
ANIP ANI Pharmaceuticals	$614.38M	2.34	$7.59 per share	8.73	$19.11 per share	3.47
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.67 per share	N/A
AXSM Axsome Therapeutics	$385.69M	14.26	N/A	N/A	$1.18 per share	94.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.85	19.68	24.25	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
ANIP ANI Pharmaceuticals	-$18.52M	-$1.27	N/A	15.75	N/A	-3.12%	21.35%	7.52%	8/5/2025 (Estimated)
ANVS Annovis Bio	-$24.59M	-$2.16	N/A	N/A	N/A	N/A	-300.56%	-193.50%	8/13/2025 (Estimated)
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	39.61	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)

Latest ANIP, ADMA, ANVS, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ADMA ADMA Biologics	$0.14	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	ANVS Annovis Bio	-$0.36	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	ANIP ANI Pharmaceuticals	$1.49	N/A	N/A	N/A	$187.18 million	N/A
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.04	N/A	N/A	N/A	$140.02 million	N/A
5/13/2025	Q1 2025	ANVS Annovis Bio	-$0.47	-$0.32	+$0.15	-$0.32	N/A	N/A
5/9/2025	Q1 2025	ANIP ANI Pharmaceuticals	$1.37	$1.70	+$0.33	$0.69	$179.75 million	$197.12 million
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.22	6.58	3.36
ANIP ANI Pharmaceuticals	1.46	2.66	1.98
ANVS Annovis Bio	N/A	10.68	10.68
AXSM Axsome Therapeutics	3.48	2.03	1.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
ANIP ANI Pharmaceuticals	76.05%
ANVS Annovis Bio	15.83%
AXSM Axsome Therapeutics	81.49%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.50%
ANIP ANI Pharmaceuticals	11.10%
ANVS Annovis Bio	20.80%
AXSM Axsome Therapeutics	22.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.73 million	230.38 million	Optionable
ANIP ANI Pharmaceuticals	600	21.66 million	19.26 million	Optionable
ANVS Annovis Bio	3	19.49 million	15.43 million	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.26 million	Optionable

ANIP, ADMA, ANVS, and AXSM Headlines

Recent News About These Companies

Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Enliven Therapeutics (ELVN)

1 hour ago | theglobeandmail.com

Lindbrook Capital LLC Decreases Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

July 20 at 9:01 AM | marketbeat.com

Bank of New York Mellon Corp Has $15.28 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

July 20 at 3:21 AM | marketbeat.com

Equities Analysts Offer Predictions for AXSM Q2 Earnings

July 16, 2025 | marketbeat.com

FY2029 Earnings Forecast for AXSM Issued By Leerink Partnrs

July 15, 2025 | americanbankingnews.com

Edgestream Partners L.P. Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

July 14, 2025 | marketbeat.com

Leerink Partnrs Issues Optimistic Forecast for AXSM Earnings

July 14, 2025 | marketbeat.com

AXSM - Axsome Therapeutics Inc Executives | Morningstar

July 12, 2025 | morningstar.comM

Bank of America Securities Keeps Their Buy Rating on Axsome Therapeutics (AXSM)

July 12, 2025 | theglobeandmail.com

Alps Advisors Inc. Sells 6,826 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

July 12, 2025 | marketbeat.com

Axsome Therapeutics Inc News (AXSM) - Investing.com

July 11, 2025 | investing.com

Stocks Showing Improving Market Leadership: Axsome Therapeutics Earns 85 RS Rating

July 10, 2025 | msn.com

Axsome Therapeutics (AXSM) Initiated with a Buy at Oppenheimer

July 9, 2025 | theglobeandmail.com

Iridian Asset Management LLC CT Has $12.40 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

July 9, 2025 | marketbeat.com

Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4

July 9, 2025 | globenewswire.com

Axsome Therapeutics (AXSM) Gets a Buy from Wells Fargo

July 9, 2025 | theglobeandmail.com

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Recommendation of "Buy" by Brokerages

July 9, 2025 | marketbeat.com

Trek Financial LLC Invests $3.45 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

July 8, 2025 | marketbeat.com

Penserra Capital Management LLC Buys Shares of 19,112 Axsome Therapeutics, Inc. (NASDAQ:AXSM)

July 8, 2025 | marketbeat.com

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by Principal Financial Group Inc.

July 8, 2025 | marketbeat.com

Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21

July 7, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP, ADMA, ANVS, and AXSM Company Descriptions

ADMA Biologics NASDAQ:ADMA

$16.73 -0.86 (-4.89%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$17.12 +0.39 (+2.33%)

As of 07/18/2025 07:55 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ANI Pharmaceuticals NASDAQ:ANIP

$66.30 -1.74 (-2.56%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$66.36 +0.06 (+0.08%)

As of 07/18/2025 04:33 PM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Annovis Bio NYSE:ANVS

$2.66 -0.15 (-5.41%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$2.70 +0.04 (+1.58%)

As of 07/18/2025 07:52 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Axsome Therapeutics NASDAQ:AXSM

$111.70 -0.54 (-0.48%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$111.42 -0.28 (-0.25%)

As of 07/18/2025 06:52 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time